Plasma-Based Diagnostics for Alzheimer’s Disease: Current State and Clinical Relevance of pTau 217

This webinar offers the following credit types: P.A.C.E.®, Florida


 

Lecture Presenters

Christine Cliatt Brown, MD

Christine Cliatt Brown, MD

Assistant Professor, Division of Cognitive Neurology
Spencer Fox Eccles School of Medicine at the University of Utah
Behavioral Neurologist
University of Utah Health

Dr. Christine Cliatt Brown is an assistant professor of Neurology in the division of Cognitive Neurology at the University of Utah and a staff neurologist at the George E. Wahlen Department of Veterans Affairs Medical Center in Salt Lake City. She graduated from the University of Colorado School of Medicine, completed her residency in neurology at the University of Utah, and completed her fellowship in Behavioral Neurology at Mayo Clinic, Rochester, MN. Dr. Cliatt Brown’s areas of interest are in early-onset and atypical presentations of dementia and normal pressure hydrocephalus (NPH). She has participated in research in primary progressive aphasia, dementia with Lewy bodies, Alzheimer’s disease biomarkers, and lifestyle modifications for cognition and dementia risk reduction


Kelly Doyle, PhD, DABCC, FADLM

Kelly Doyle, PhD, DABCC, FADLM

Associate Professor (Clinical)
Spencer Fox Eccles School of Medicine at the University of Utah
Medical Director, Special Chemistry, Endocrinology, and Mass Spectrometry
ARUP Laboratories

Dr. Kelly Doyle is a medical director of special chemistry, endocrinology, and mass spectrometry at ARUP Laboratories and an associate professor (clinical) at the University of Utah School of Medicine. Dr. Doyle received his doctorate degree in medicinal chemistry from the University of Utah. He then completed a clinical chemistry fellowship at the University of Utah School of Medicine and an oncological sciences fellowship at the Huntsman Cancer Institute. Dr. Doyle is board certified and a member of the Association for Diagnostics & Laboratory Medicine. His research interests include clinical application and implementation of mass spectrometry, emerging biomarkers, endocrinology, and laboratory best practices.


Objectives

After this presentation, participants will be able to:

  • Explain recent changes in AD diagnostic criteria
  • Describe the role of fluid biomarkers in the diagnosis of AD
  • Summarize the sequence of biomarker changes across the disease course in AD
  • Select patients appropriate for pTau 217 testing

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories